First and only oral therapy approved for mild, moderate, and severe plaque psoriasis, and active PsA SEE THE DATA
How do you evaluate patients for psoriatic arthritis?
Explore the numbers
of patients with psoriatic arthritis develop psoriasis before experiencing joint symptoms 3
of patients with psoriatic arthritis may present with scalp psoriasis 4,5
The risk of psoriatic arthritis in patients with psoriasis can be ~4x higher for patients with scalp involvement 6,*
of patients with psoriatic arthritis showed signs of nail psoriasis 7
The presence of nail psoriasis can help clinicians with diagnosing psoriatic arthritis 8
*Plaque psoriasis diagnoses were validated through a medical-record analysis of 1,633 patients. Incident and clinically recognized patients with PsA were classified according to CASPAR. Cox proportional hazards models were used to identify predictors of PsA within the plaque psoriasis cohort.
PsA IS MORE THAN JOINTS 9
Joint tenderness and swelling
PsA, psoriatic arthritis.
Warnings and Precautions
Use in Specific Populations
Please click here for the full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for
phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
References: 1. Mease PJ, Armstrong AW. Drugs. 2014;74(4):423-441. 2. Arthritis Foundation. arthritis.org. Accessed December 6, 2022. 3. National Psoriasis Foundation. psoriasis.org. Accessed December 8, 2022. 4. Yang Q, Qu L, Tian H, et al. J Eur Acad Dermatol Venereal. 2011;25(12):1409-1414. 5. Spelman L, Su JC, Fernandez-Penas P, et al. J Eur Acad Dermatol Venereal. 2015:29(11):2184-2191. 6. Wilson FC, Icen M, Crowson CS, et al. Arthritis Rheum. 2009; 61(2):233-239. 7. Sobolewski P, Walecka I, Oopytalska K. Reumatologia. 2017;55(3):131-135. 8. Gottlieb A, Korman NK, Gordon KB, et al. J Am Acad Dermatol. 2008;58(51):851-864. 9. Kavanaugh A, Helliwell P, Ritchlin CT. Rheumatol Ther. 2016;3(1):91-102. 10. Ogdie A, Shin D, Choi H, et al. Ann Rheum Dis. 2019. doi:10.1136/annrheumdis-2019-eular.4991 11. Husni ME, Fernandez A, Hauber B, et al. Arthritis Res Ther. 2018;20(1):102. 12. Sakkas LI, Alexiou I, Simopoulou T, et al. Arthritis Rheum. 2013;43(3):325-334. 13. Gottlieb AB, Merola JF. J Am Acad Dermatol. 2021;84(1):92-101. 14. Coates LC, Kavanaugh A, Mease PJ, et al. Arthritis Rheumatol. 2016;68(5):1060-1071. 15. Husted JA, Tom BD, Schentag CT, et al. Ann Rheum Dis. 2009;68(10):1553-1558. 16. Lebwohl MG, Bachelez H, Barker J, et al. J Am Acad Dermatol. 2014;70(5):871-881.